LLY

1,064.11

+2.13%↑

JNJ

234.43

+1.74%↑

ABBV

216.94

+0.77%↑

UNH

388.84

+1.3%↑

AZN

188.07

-0.94%↓

LLY

1,064.11

+2.13%↑

JNJ

234.43

+1.74%↑

ABBV

216.94

+0.77%↑

UNH

388.84

+1.3%↑

AZN

188.07

-0.94%↓

LLY

1,064.11

+2.13%↑

JNJ

234.43

+1.74%↑

ABBV

216.94

+0.77%↑

UNH

388.84

+1.3%↑

AZN

188.07

-0.94%↓

LLY

1,064.11

+2.13%↑

JNJ

234.43

+1.74%↑

ABBV

216.94

+0.77%↑

UNH

388.84

+1.3%↑

AZN

188.07

-0.94%↓

LLY

1,064.11

+2.13%↑

JNJ

234.43

+1.74%↑

ABBV

216.94

+0.77%↑

UNH

388.84

+1.3%↑

AZN

188.07

-0.94%↓

Search

Bio-Techne Corp

Open

SectorHealthcare

47.97 1.59

Overview

Share price change

24h

Current

Min

46.87

Max

48.09

Key metrics

By Trading Economics

Income

13M

51M

Sales

16M

311M

P/E

Sector Avg

63.471

49.701

EPS

0.53

Dividend yield

0.74

Profit margin

16.392

Employees

3,100

EBITDA

22M

100M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+26.87% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.74%

2.39%

Next Earnings

5 Aug 2026

Next Dividend date

29 May 2026

Market Stats

By TradingEconomics

Market Cap

-1.6B

7B

Previous open

46.38

Previous close

47.97

News Sentiment

By Acuity

50%

50%

148 / 345 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Bio-Techne Corp Chart

Past performance is not a reliable indicator of future results.

Related News

7 Nov 2025, 22:36 UTC

Earnings

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

Peer Comparison

Price change

Bio-Techne Corp Forecast

Price Target

By TipRanks

26.87% upside

12 Months Forecast

Average 59.25 USD  26.87%

High 70 USD

Low 49 USD

Based on 10 Wall Street analysts offering 12 month price targets forBio-Techne Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

10 ratings

6

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

49.67 / 50.24Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

148 / 345 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat